Buchumschlag

Comparative Effectiveness of First‐Line Pembrolizumab vs. Chemotherapy in aNSCLC : A Norwegian Population‐Based Cohort Study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Simon Boge Brant, Siri Børø, Christian Jonasson, Åslaug Helland, Steinar Thoresen
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
von: Jincheng Yang, et al.
Veröffentlicht: (2025)

Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR ‐Mutated NSCLC ”
von: Azar Shahraz, et al.
Veröffentlicht: (2025)

Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia
von: Chin Hang Yiu, et al.
Veröffentlicht: (2026)

Correction to “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia”
Veröffentlicht: (2026)

Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab
von: Aymara Sancho‐Araiz, et al.
Veröffentlicht: (2024)

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data
von: Maria J. Alfonso Arvez, et al.
Veröffentlicht: (2025)

Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers
von: Sébastien Benzekry, et al.
Veröffentlicht: (2024)

Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second‐Line Treatment of Advanced Non–Small Cell Lung Cancer
von: Euloge Clovis Kenne Pagui, et al.
Veröffentlicht: (2025)

Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population‐Based Cohort Study
von: Hyesung Lee, et al.
Veröffentlicht: (2025)

Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain
von: Sachalee Campbell, et al.
Veröffentlicht: (2026)

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real‐World Data
von: Francesco Pignatti, et al.
Veröffentlicht: (2026)

Population‐Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study
von: Rishi J. Desai, et al.
Veröffentlicht: (2025)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
von: Huy X. Ngo, et al.
Veröffentlicht: (2024)

Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis
von: Raj Desai, et al.
Veröffentlicht: (2024)

Infrequent Resolution of Vaso‐Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa‐Cel Trial Population: A Cohort Study of Medicaid Enrollees
von: Mufaddal Mahesri, et al.
Veröffentlicht: (2024)

A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition
von: Stef Schouwenburg, et al.
Veröffentlicht: (2024)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT ‐ ACS Emulation Using National Health Insurance Claims Data
von: Li‐Wen Huang, et al.
Veröffentlicht: (2025)

Corrigendum: “Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model‐Based Meta‐Analysis of American College of Rheumatology Response Criteria”
Veröffentlicht: (2024)

Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population
von: Sumudu Rangika Samarasinghe, et al.
Veröffentlicht: (2024)

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants
von: Ziheng Hu, et al.
Veröffentlicht: (2026)

Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations
von: Kaio Evandro Cardoso Aguiar, et al.
Veröffentlicht: (2026)

Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate
von: Esben Iversen, et al.
Veröffentlicht: (2024)

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
von: Amy C.D. Peeters, et al.
Veröffentlicht: (2025)

Populations Addressed in Vaccines Approved via the European Medicines Agency
von: Débora D. Gräf, et al.
Veröffentlicht: (2025)

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis
von: Jenny‐Hoa Nguyen, et al.
Veröffentlicht: (2026)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes
von: Shih‐Hsuan Lin, et al.
Veröffentlicht: (2026)

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans
von: Sihan Chen, et al.
Veröffentlicht: (2026)

Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model
von: Thomas K. Henthorn, et al.
Veröffentlicht: (2025)

Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study
von: Jieni Li, et al.
Veröffentlicht: (2024)

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study
von: Bar Rosh, et al.
Veröffentlicht: (2026)

QTc Interval Changes in Preeclampsia vs. Normal Pregnancy: A Systematic Review and Meta‐Analysis
von: Omar A. Aboshady, et al.
Veröffentlicht: (2025)

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects
von: Emma C. Bernsen, et al.
Veröffentlicht: (2025)

Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling
von: Suwasin Udomkarnjananun, et al.
Veröffentlicht: (2024)

Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
von: Miquel Serra‐Burriel, et al.
Veröffentlicht: (2026)

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis
von: Milou A. Hogervorst, et al.
Veröffentlicht: (2025)

A Fast Path from Innovation to Safe and Effective Medicines
von: Peter Arlett, et al.
Veröffentlicht: (2025)

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data
von: Michael I. Sponfeldner, et al.
Veröffentlicht: (2025)

Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID‐19: A Nationwide Cohort Study in South Korea
von: Ju Hwan Kim, et al.
Veröffentlicht: (2024)

Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
von: Tetsuro Ogawa, et al.
Veröffentlicht: (2025)

Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit /Hyperactivity Disorder
von: Shen Cheng, et al.
Veröffentlicht: (2024)